← Leaderboards
Steven Edward Johnson
Durametrix Llc
$2,215,316
Attributed
$2,215,316
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,215,316 · 2
By mechanism
R42$1,958,141 · 1
R41$257,175 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Imaging Technology”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$314,257,071
- Joel A Lipkin · Four Points Technology, Llc$184,504,844
- Lynn Briscoe · Leidos Biomedical Research, Inc.$116,524,368
- Terry Drinkwine · Carahsoft Technology Corporation$93,741,163
Research focus
Imaging TechnologyInvestigational DrugsGrantImaging ApproachIndustrializationInnovationDrug ToxicityExtracellular SpaceDrug TestingHistopathologyDuramycinCollaborative EnvironmentCell SurvivalEarly DiagnosisConsumptionCostCytotoxic AgentClimateClinically RelevantDesignDosageCell DeathCellsInvestigational New Drug Application
Grant awards (3)
Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage$946,480
R42 · FY2025 · GM · contact PI
Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage$1,011,661
R42 · FY2024 · GM · contact PI
Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage$257,175
R41 · FY2021 · GM · contact PI